Aclaris Therapeutics
$18.029876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$18.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.86 (-4.57%) Today
+$0.05 (+0.28%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell ACRS and other stocks, options, and ETFs commission-free!
About ACRS
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA. The listed name for ACRS is Aclaris Therapeutics, Inc. Common Stock.
CEO
Neal S. Walker
Employees
77
Headquarters
Malvern, Pennsylvania
Founded
2012
Market Cap
771.26M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
11.84M
High Today
$24.27
Low Today
$17.71
Open Price
$19.98
Volume
20.42M
52 Week High
$24.27
52 Week Low
$0.70
Collections
ACRS News
ACRS Earnings
-$1.24
-$0.83
-$0.41
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market